Aripiprazole-associated dyskinesia [5]

Annals of Pharmacotherapy

Volumn 39, Issue 1, 2005, Pages 200-201

  Sajbel, Terne A ^a   Cheney, Elisabeth M ^a   DeQuardo, John R ^a  

^a Colorado Mental Health Institute at Pueblo   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; DESIPRAMINE; FLUOXETINE; OLANZAPINE; QUETIAPINE; SERTRALINE; TRIFLUOPERAZINE;

ADULT; CASE REPORT; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LETTER; MALE; MONOTHERAPY; NEUROIMAGING; PRIORITY JOURNAL; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SLEEP; TONGUE; TREATMENT OUTCOME; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; DYSKINESIA, DRUG-INDUCED; HUMANS; MALE; PIPERAZINES; PSYCHOTIC DISORDERS; QUINOLONES;

EID: 11144248926     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E288     Document Type: Letter

References (5)

1. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:763-71.
2. Argo TR, Carnahan RM, Perry PJ. Aripiprazole, a novel atypical antipsychotic drug. Pharmacotherapy 2004;24:212-28.
3. Duggal HS. Aripiprazole-induced improvement in tardive dyskinesia. Can J Psychiatry 2003;48:771-2.
4. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
5. Lam YWF. Clinical pharmacology of dopamine agonists. Pharmacotherapy 2000;20(1 pt 2):17S-25S.